Journal Article

Voriconazole: A New Triazole Antifungal Agent

Louis D. Saravolatz, Leonard B. Johnson and Carol A. Kauffman

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 5, pages 630-637
Published in print March 2003 | ISSN: 1058-4838
Published online March 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/367933
Voriconazole: A New Triazole Antifungal Agent

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The 1990s witnessed an expansion of the antifungal armamentarium to include 2 new azole agents, fluconazole and itraconazole. These agents changed our approach to treating many fungal infections. However, neither was an ideal agent. Itraconazole was plagued by absorption problems; fluconazole had a limited spectrum of antifungal activity, and resistance was soon noted in immunosuppressed hosts who received long-term treatment. Second-generation triazole agents have been in development for the past decade. The first of these new agents to receive approval from the US Food and Drug Administration (FDA) is voriconazole, a synthetic derivative of fluconazole. Replacement of one of the triazole rings with a fluorinated pyrimidine and the addition of an α-methyl group resulted in expanded activity, compared with that of fluconazole. The development of voriconazole proceeded primarily because of this broadened antifungal spectrum.

Journal Article.  4474 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.